Tolerability and safety of urotainer® polihexanide 0.02% in catheterized patients: a prospective cohort study.

In patients with indwelling bladder catheters for > 2 weeks, bacterial colonization is inevitable, leading to urinary tract infections or encrustations with subsequent catheter blockage. Currently, bladder irrigations are the most frequently used prophylactic means, but the best solution remains yet to be determined. In vitro studies demonstrate that polihexanide is a promising option for catheter irrigation, but no data about safety and tolerability exist.

In a prospective observational study in patients with indwelling bladder catheter for > 2 weeks, a 0.02% polihexanide solution was used to rinse the catheter on five consecutive days. Adverse events, tolerability and vital signs were assessed before, during, after and at the end of the treatment period.

There was no serious adverse event in the study. A total of 28 adverse events (AEs) in 15 (46.88%) participants were experienced. Absolute changes in pain scores were not clinically relevant. No incidences of either flushing or sweating were found during instillation. Bladder spasms during instillation were reported in two cases during a single instillation. Mean pulse rates did not change by more than 3 beats per minute. Mean changes in body temperature did not exceed 0.12 °C. Clinically relevant changes in blood pressure were recorded for 3 patients.

This is the first study to demonstrate that a 0.02% polihexanide solution can safely be used for catheter irrigation. ( NCT02157415 ), June 6th, 2014.

BMC urology. 2020 Jul 08*** epublish ***

Jürgen Pannek, Karel Everaert, Sandra Möhr, Will Vance, Frank Van der Aa, Jürg Kesselring

Neuro-Urology, Swiss Paraplegic Centre, Guido A. Zäch Strasse 1, CH - 6207, Nottwil, Switzerland. ., Urologie, Universitair Ziekenhuis, Gent, Belgium., Schweizerisches Paraplegikerzentrum REHAB, Basel, Switzerland., Urology, Kliniken Beelitz GmbH, Beelitz-Heilstätten, Beelitz, Germany., National Multiple Sclerose Centrum, Melsbroek, Belgium., Department of Neurology & Neurorehabilitation, Kliniken Valens, Valens, Switzerland.